Monday, March 2, 2026

SynAct Pharma appoints Ann Kristin Led as CFO

SynAct Pharma AB (Nasdaq Stockholm: SYNACT) has appointed Ann Kristin Led as Chief Financial Officer (CFO), effective 1 March 2026.

Background across life sciences and capital markets

According to the company, Led is an experienced finance executive with a track record in life sciences, pharmaceuticals, and med-tech. She has held senior positions at MedTrace Pharma, MC2 Therapeutics, and Lundbeck, where she worked on financial strategy and organisational growth. Her experience includes fundraising activities, licensing and transaction processes, and oversight of financial operations.

Finance leadership transition

CEO Jeppe Øvlesen thanked Björn Westberg for his work as CFO over the years and noted Malin Wikstrand’s contribution in the interim CFO role.

Clinical milestones and partnering talks

SynAct expects key clinical data from its Phase 2b ADVANCE study by the end of Q2. The company also cited ongoing strategic discussions with potential partners.